相关实验视频

Updated: Jun 4, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

癌症目标端粒酶的新型抑制剂的识别,使用基于双结构的药方法来虚拟选图书馆,分子对接和通过分子动力学模拟进行验证

Divpreet Kaur^1,2, Daman Saluja¹, Madhu Chopra²

¹Medical Biotechnology Laboratory, Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi, India.

Journal of biomolecular structure & dynamics

|December 20, 2024

概括

研究人员确定了端粒酶抑制剂的新结合部位,克服了开发向端粒酶活性的抗癌药物的重大障碍. 这一发现为新的癌症疗法铺平了道路.

科学领域:

生物化学和分子生物学
药用化学医学化学
计算机化药物发现技术

背景情况:

端粒酶活性对癌细胞不朽性至关重要,使其成为抗癌疗法的关键标.
小分子端粒酶抑制剂的开发一直受到结构模糊性和缺乏精确的结合位点信息的阻碍.

研究的目的:

使用分子动力学来确定端粒酶抑制剂BIBR1532的精确结合部位.
通过对已识别的结合口袋进行化学图书馆的虚拟选,发现用于抗癌药物开发的新化合物.

主要方法:

利用分子动力学模拟来确定BIBR1532在端粒酶催化子单元 (hTERT) 上的结合部位.
为假定和新识别的结合口袋生成和验证的药模型.
进行了化学库的虚拟选,随后进行了药物相似性过,重塑和广泛的分子动力学模拟,以验证化合物.

主要成果:

确定了BIBR1532的新型结合点,与之前报告的FVYL口袋不同,位于hTERT.的指域内.
发现和验证的新型化合物在这个扩展的FVYL口袋中表现出显著的相互作用.
有约束力的自由能量计算和模拟后分析 (PCA,FEL) 证实了化合物的稳定性和相互作用.

结论:

已经阐明了BIBR1532的精确结合部位,为端粒酶抑制提供了新的见解.
针对扩展FVYL口袋的新型化合物被确定并通过计算验证.
这些化合物代表了进一步的实验室验证和抗癌药物开发进步的有希望的候选人.

关键词:

药物发现药物发现分子对接的分子对接.分子动力学模拟模拟小分子抑制剂小分子抑制剂端粒酶的使用方法虚拟选虚拟选虚拟选

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...